Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

N8659

Sigma-Aldrich

Nimustine hydrochloride

solid

Synonym(s):

N′-[(4-Amino-2-methyl-5-pyrimidinyl)methyl]-N-(2-chloroethyl)-N-nitrosourea hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C9H13ClN6O2
CAS Number:
55661-38-6
Molecular Weight:
272.69
MDL number:
MFCD01676942
UNSPSC Code:
12352200
PubChem Substance ID:
24278598

form

solid

SMILES string

Cl.Cc1ncc(CNC(=O)N(CCCl)N=O)c(N)n1

InChI

1S/C9H13ClN6O2.ClH/c1-6-12-4-7(8(11)14-6)5-13-9(17)16(15-18)3-2-10;/h4H,2-3,5H2,1H3,(H,13,17)(H2,11,12,14);1H

InChI key

KPMKNHGAPDCYLP-UHFFFAOYSA-N

Application

Nimustine hydrochloride is an antineoplastic.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301

Precautionary Statements

P301 + P310

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
031M1172V
100M1242
060M1310
012K1141
078K1343

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Nancy Berte et al.
Molecular cancer therapeutics, 15(11), 2665-2678 (2016-11-04)
Malignant gliomas exhibit a high level of intrinsic and acquired drug resistance and have a dismal prognosis. First- and second-line therapeutics for glioblastomas are alkylating agents, including the chloroethylating nitrosoureas (CNU) lomustine, nimustine, fotemustine, and carmustine. These agents target the
Marina Pajic et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 23(22), 7020-7033 (2017-08-20)
Purpose: We aimed to characterize and target drug-tolerant BRCA1-deficient tumor cells that cause residual disease and subsequent tumor relapse.Experimental Design: We studied responses to various mono- and bifunctional alkylating agents in a genetically engineered mouse model for BRCA1/p53-mutant breast cancer.
A Shiraishi et al.
Carcinogenesis, 21(10), 1879-1883 (2000-10-07)
O(6)-methylguanine-DNA methyltransferase plays vital roles in preventing induction of mutations and cancer as well as cell death related to alkylating agents. Mice defective in the MGMT: gene, encoding the methyltransferase, were used to evaluate cell death-inducing and tumorigenic activities of
Bastiaan Evers et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 16(1), 99-108 (2009-12-17)
Hereditary breast cancer is partly explained by germline mutations in BRCA1 and BRCA2. Although patients carry heterozygous mutations, their tumors have typically lost the remaining wild-type allele. Selectively targeting BRCA deficiency may therefore constitute an important therapeutic approach. Clinical trials
Hajime Asada et al.
The Journal of veterinary medical science, 77(6), 677-684 (2015-02-27)
Canine histiocytic sarcoma (HS) is an aggressive tumor type originating from histiocytic cell lineages. This disease is characterized by poor response to chemotherapy and short survival time. Therefore, it is of critical importance to identify and develop effective antitumor drugs
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service